Claimed effect · Linaclotide

Does Linaclotide help with systemic effects?

A
Grade A — established in humansLabel pharmacokinetics · effect size: not measurable
Short answerEstablished in humans. Label pharmacokinetics point the same way: no measurable effect, or none yet shown. The Linzess label describes the drug as minimally absorbed with negligible systemic availability, so no half-life can be calculated. A peptide drug with essentially no systemic exposure — the reason its safety profile is a gastrointestinal one.

What the studies show

The Linzess label describes the drug as minimally absorbed with negligible systemic availability, so no half-life can be calculated. A peptide drug with essentially no systemic exposure — the reason its safety profile is a gastrointestinal one.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Linzess (linaclotide) prescribing information.DailyMed, read 29 Oct 2026Oral route, negligible systemic availability, indications and the contraindication under 2 years of age.

In context

Linaclotide is a 14-amino-acid peptide with three disulfide bonds, approved since 2012 as Linzess and Constella for irritable bowel syndrome with constipation and for chronic idiopathic constipation. It is taken as a capsule and is minimally absorbed — it acts on guanylate cyclase-C receptors on the luminal surface of the intestine. In a 26-week phase 3 trial, 33.7% of treated patients met the FDA responder endpoint against 13.9% on placebo. Diarrhoea is the dose-limiting effect.

Linaclotide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Linaclotide proven to help with systemic effects?
Yes, as far as human trials can show it: Label pharmacokinetics. LYO grades this outcome A.
What studies are behind the grade?
The Linzess label describes the drug as minimally absorbed with negligible systemic availability, so no half-life can be calculated. A peptide drug with essentially no systemic exposure — the reason its safety profile is a gastrointestinal one.
Is Linaclotide approved for this?
Linaclotide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Linaclotide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →